Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a...
Lukang Pharmaceutical
Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development
China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...
Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case
Sichuan Gowell Pharmaceutical Co., Ltd. has secured a favorable final judgment in its appeal against...